Avadel Pharmaceuticals PLC
NASDAQ:AVDL

  • LAST PRICE
    15.7600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    14.2200/ 1
  • Ask / Lots
    16.7500/ 2
  • Open / Previous Close
    0.0000 / 15.7600
  • Day Range
    ---
  • 52 Week Range
    9.5000
    19.0900
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
AVDL
Avadel Pharmaceuticals PLC
1.5B
-8.5x
---
TARS
Tarsus Pharmaceuticals Inc
1.3B
-7.4x
---
LGND
Ligand Pharmaceuticals Inc
1.5B
16.0x
-12.71%
LQDA
Liquidia Corp
982.3M
-8.2x
---
PBAJ
Petro USA Inc
1.0B
-31,250.0x
---
OCUL
Ocular Therapeutix Inc
898.4M
-5.3x
---
As of 2024-05-31

Company Information

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Contact Information

Headquarters
Block 10-1 Blanchardstown Corporate Park BallycoolinDUBLIN, Ireland 15
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Geoffrey Glass
Chief Executive Officer, Director
Gregory Divis
Chief Financial Officer
Thomas McHugh
Chief Commercial Officer
Richard Kim
Independent Director
Naseem Amin

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.5B
Revenue (TTM)
$55.1M
Shares Outstanding
96.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.76
EPS
$-1.86
Book Value
$0.98
P/E Ratio
-8.5x
Price/Sales (TTM)
27.5
Price/Cash Flow (TTM)
---
Operating Margin
-269.70%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.